LUPIN LIMITED
Latest filings
Next results: Tue, 3 Nov · Financial Results/Other business matters- U.S. FDA closes Goa plant inspection with one observation · Regulatory & Legal
- Lupin allots 3,033 shares under employee stock options · Capital Market Events
- Lupin appoints Brian Savage as President and Chief Legal Officer · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Develops, manufactures and sells generic pharmaceutical formulations and active pharmaceutical ingredients, with operations spanning the United States, India and emerging markets. Pharmaceuticals accounted for 99.5% of FY26 segment revenue at ₹27,812.36 crore, with the remaining 0.5% from 'Others' which posted a small operating loss. The US franchise grew around 40% year-on-year on the back of products such as Tolvaptan, Mirabegron and Risperdal Consta; the India prescription business grew 14.5% year-on-year at 1.3x IPM and emerging markets grew 49% in Q4 FY26 led by Brazil (113% in local currency). Semaglutide was launched in India under the brand Semanext, the VISUfarma acquisition added an ophthalmology franchise, and the biosimilar franchise is currently around USD 50 million. The principal cost lines are other operating expenses at 25.9% of revenue and raw materials (mainly APIs) at 16.5%, with R&D running at around 8% of sales.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from LUPIN LIMITED's filed financials and exchange disclosures
What does LUPIN LIMITED do?
LUPIN LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LUPIN.
Is LUPIN LIMITED profitable?
Yes. Over the trailing twelve months LUPIN LIMITED reported a net profit of ₹5,551 Cr on revenue of ₹29,967 Cr.
Does LUPIN LIMITED pay a dividend?
Yes. The dividend yield is 0.61% at the current price. It paid out 10% of its profit as dividend in FY26.
Is LUPIN LIMITED debt-free?
No. It reported borrowings of ₹5,910 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹1,742 Cr after cash. Debt stands at 0.26× equity. That is higher than 64% of its 166 Pharmaceuticals peers.
Is LUPIN LIMITED expensive compared with its peers?
On trailing P/E, LUPIN LIMITED ranks 36 of 158 in Pharmaceuticals — cheaper than 78% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the LUPIN LIMITED share price move in a day?
On a typical session LUPIN LIMITED moves 0.80% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are LUPIN LIMITED's next results?
Financial Results/Other business matters on Tue, 3 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track LUPIN LIMITED's announcements?
Every NSE and BSE filing by LUPIN LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.